Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know

By clicking the continue button above, I certify I have read the CME/CE/MOC statements below.



Release Date: October 15, 2020
Expiration Date: October 15, 2021


PROGRAM DESCRIPTION
Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special attention, particularly because symptoms of COVID-19 infection are similar to common adverse events associated with lung cancer treatment.

This activity, “Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know” will provide clinicians with the most up-to-date guidance on managing lung cancer during the current pandemic, including information on the pathophysiology of Sars-Cov-2, the risk of infection in patients with lung cancer, and strategies to manage patient care and counsel through telemedicine.

AGENDA
Welcome and Introduction
Understanding the Pathophysiology of COVID-19
Recognizing the Risk of COVID-19 in Patients with Lung Cancer
Managing Patients with Lung Cancer During the COVID-19 Pandemic
Q&A Session and Concluding Remarks

PROGRAM FACULTY
 Sandra Cuellar, PharmD, BCOP
 Associate Professor
 University of Illinois at Chicago College of Pharmacy
 Clinical Oncology Pharmacist, UI Health
 Chicago, IL


Sandra Cuellar, PharmD, BCOP is a Clinical Associate Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy. Dr. Cuellar received her Pharm.D. degree from the University of Illinois at Chicago College of Pharmacy. She then completed a Pharmacy Practice Residency at University of Kentucky Chandler Medical Center. Following her residency, she completed a specialty oncology residency at MD Anderson Cancer Center in Houston, Texas. Dr. Cuellar is a Board Certified Oncology Pharmacist since 2006. Dr. Cuellar has been active in the field of hematology/oncology for 18 years. She currently is the coordinator/professor for the oncology therapeutics course as well as an oncology clinical pharmacist at UI Health. In addition, Dr. Cuellar is the director of the oncology specialty residency program, member of the DSMC, and vice-chair of IRB at UIC. Dr. Cuellar is an editor at large for Journal of Hematology Oncology Pharmacy and is involved in research, consulting and publications in the field of hematology/oncology. She is an invited lecturer to several national organizations including ASHP, ACCP, ACCC, and AMCP. She has provided multiple national and international presentations on cardio-oncology, supportive care oncology, biosimilars, and oncology therapeutics. In addition, Dr. Cuellar serves as an ASHP oncology residency surveyor and chair of the industry relation council for the Hematology Oncology Pharmacy Association.

 J. Morgan Freiman, MD, MSc
 Infectious Diseases Physician
 Director of Antimicrobial Stewardship
 Lahey Hospital and Medical Center
 Assistant Professor of Medicine
 Tufts University School of Medicine
 Boston, MA

J. Morgan Freiman, MD, MSc is an Infectious Diseases physician and the Director for the Antimicrobial Stewardship Program at Lahey Hospital and Medical Center in Burlington, MA. She trained in infectious diseases and epidemiology at Boston Medical Center and Boston University School of Public Health, prior to joining the faculty at Tufts Medical School. She worked on the front lines during the COVID-19 pandemic providing care for hundreds of patients and lead a multi-disciplinary committee to create and implement treatment guidelines for her home institution.

 Antonio Passaro, MD, PhD
 Division of Thoracic Oncology
 European Institute of Oncology
 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
 Milan, Italy




Antonio Passaro, MD, PhD is a consultant medical oncologist in the Division of Thoracic Oncology at European Institute of Oncology, Milan, Italy. He is a clinician and researcher specializing in lung cancer with a special commitment on target therapies and predictive biomarkers. He has been a Member of the ESMO Lung Cancer Faculty and SARS-CoV-2 and cancer Scientific Committee. He also serves on the Guideline scientific committee for Lung Cancer for the Italian Association of Medical Oncology (AIOM). He is involved in several national and international specialist groups dedicated to lung cancer. He is an author of many peer-reviewed publications and is actively involved in lung cancer clinical trials and translational research. He is an active supporter and connoisseur of social media in healthcare and oncology for which he has carried out national and international in-depth reports and workshops. Dr Passaro is dedicated to improving cancer care addressing the needs of individual patients that remains the forefront of his philosophy of care. Based on his PhD background on molecular medicine, his research interests focus on the identification and improvement of molecular target, and related therapeutics to improve understanding of precision and clinical research in lung cancer. Disclosure of Interest: Antonio Passaro received honoraria for speaker’s engagement or for providing consultancy from Agilent/Dako, AstraZeneca, BMS, MSD Lilly, Pfizer and Roche.

 Beth Sandy, MSN, CRNP
 Nurse Practitioner
 Abramson Cancer Center
 University of Pennsylvania
 Philadelphia, PA



Beth Sandy, MSN, CRNP is a thoracic oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania. She has published and speaks nationally on the topic of lung cancer the supportive care needs of lung cancer patients. She serves is several editorial roles with peer-reviewed publications as well.

TARGET AUDIENCE
This activity is intended for clinicians responsible for the daily management of patients with lung cancers.

EDUCATIONAL OBJECTIVES
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

This program is designed to address ACPE competencies, including foundational knowledge and essentials for practice and care. At the conclusion of this education, participants should be able to:
  • Discuss the most current understanding of the pathophysiology of COVID-19
  • Recognize and evaluate factors that increase risk of COVID-19 among patients with lung cancer
  • Integrate consensus recommendations for the safe and effective management of patients with lung cancer during the COVID-19 pandemic
  • Provide counsel to patients with lung cancer regarding concerns or fears related to COVID-19

PHYSICIAN ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN DESIGNATION STATEMENT
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu

ABIM MOC DESIGNATION STATEMENT
 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

PHARMACIST ACCREDITATION STATEMENT
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


PHARMACIST CREDIT DESIGNATION
The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 contact hour (0.10 CEUs) of continuing education credit (UAN number 0418-9999-20-006-H01-P).

This is a knowledge-based activity.

For information about this continuing pharmacy education (CPE) activity, please email: contact@potomacme.org.

NURSING CREDIT STATEMENT
This nursing continuing professional development activity was approved by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE INFORMATION
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
 
 Faculty and Steering Committee Disclosures 
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Sandra Cuellar, PharmD, BCOP: Nothing to disclose

J. Morgan Freiman, MD, MSc: Nothing to disclose

Antonio Passaro, MD, PhD: Consultant: Agilent, AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Pfizer, Roche

Beth Sandy, MSN, CRNP: Speaker's Bureau: AstraZeneca, Merck, Takeda

Umit Tapan, MD, BUSM CME Course Director: Nothing to disclose
 
Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chelsey Goins, PhD; Elizabeth Drury; Natalie Sanfratello, MPH; Janice Agazio, PhD, CRNP, RN, FAANP, FAAN: Nothing to disclose  
Content Reviewers
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Katie Propst, PhD: Nothing to disclose

DISCLAIMER
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

HARDWARE/SOFTWARE REQUIREMENTS
Please ensure the computer system you plan to use meets the following minimum requirements:
  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT AND MOC POINTS
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade of 75%) and program evaluation. Certificates can be printed immediately.

PROVIDER
Jointly provided by Boston University School of Medicine, Potomac Center for Medical Education, and Rockpointe

 

This nursing continuing professional development activity was approved by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

In collaboration with the American Lung Association



Click here for the PCME Privacy Policy

SUPPORTER
This program is supported by an educational grant from Daiichi Sankyo, Inc.
 

 


Facebook - RockPointe Twitter - RockPointe LinkedIn - RockPointe